Emma Teasdale

Aug 27, 2024 | bjgp.org | Emma Teasdale |Hazel Everitt |Sarah Alderson |Alexander Ford

AbstractBackground: Irritable bowel syndrome (IBS) can cause troublesome symptoms impacting patients’ quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second line treatment, but this is rarely prescribed in primary care. Aim: To explore patients’ and general practitioners’ (GPs) views and experiences of using low-dose amitriptyline for IBS.